Drug Profile
SM 04755
Alternative Names: SM-04755Latest Information Update: 19 Apr 2021
Price :
$50
*
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis; Psoriasis; Scleroderma; Tendinitis
- Discontinued Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer
Most Recent Events
- 15 Apr 2021 Samumed is now called Biosplice Therapeutics
- 28 Dec 2020 No recent reports of development identified for preclinical development in Psoriasis in USA (Topical)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Scleroderma in USA (Topical)